[Congress] Start.Smart.Global 2019 – 7-10 October 2019: Roadshow in Japan & November 2019: Roadshow in South Korea

[Congress] Start.Smart.Global 2019 – 7-10 October 2019: Roadshow in Japan  & November 2019: Roadshow in South Korea

Oncodesign participates to the Start.Smart.Global initiative by EIT Health in Japan and in South Korea.

Seeking for partners on drug discovery programs based on our Nanocyclix platform as next-generation kinase inhibitors?

Using its Nanocyclix® technology, Oncodesign identifies small macrocyclic molecules capable of inhibiting both known and unexplored kinases in a powerful and targeted manner

A large variety of kinase inhibitors are thus explored continuously, and the most promising inhibitor/targeted kinase combinations are selected for more in depth investigations. 

Oncodesign has built a project portfolio with promising potential to treat diseases with very substantial unmet medical needs. This portfolio contains both molecules already at an advanced stage of clinical development and molecules at an earlier stage of development.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Our partners

EIT Health & Medicen granted us a financial support to develop our access to Asian Markets

EIT Health logo

EIT Health is a network of best-in-class health innovators backed by the EU. We deliver solutions to enable European citizens to live longer, healthier lives.

logo medicen bleu

It is a network unique in Europe in terms of its scope, experience and core competencies. Thanks to the involvement of its members, EIT Health intends to act as a catalyst for the implementation of new technologies and innovative solutions in health, to benefit European citizens and to respond to the main challenges of the sector on the continent.

[Symposium] - UPDATED 09/14/2020 - Innovative & integrated solution providers in translational research to develop immunotherapies - 30 September - Paris - France

Toward Next Generation of Solution Providers

[Symposium] [EN] Innovative & integrated solution providers in translational research to develop immunotherapies - 30 Septembre - Paris

The aim of this symposium was to address the current trends in Immunotherapies discovery & development from an academic, industrial and regulatory affairs point of view. Discover how collaborative research organizations can bring their added values within this context, and read the news report to know more about the research, findings & insights of the three key leaders opinion.

News report – Innovative Solution Providers’ symposium focused on immunotherapies

On September 30, 2019, 100 scientific professionals gathered in Paris for the 1st edition of a unique symposium to discuss ‘Innovative & Integrated Solution Providers in Translational Research to Develop Immunotherapies – Toward Next Generation of Solution Providers.

Exploring the current trends in immunotherapies discovery & development from an academic, industrial & regulatory affairs point of view, the event was well received. Three expert speakers took to the stage to share research, findings & insights.

Dr Laurence Laigle, director of translational & clinical research, Center for Therapeutic Innovation, Immuno-Inflammatory Diseases, Servier, shared her views on the 'Clinical Development of Immunotherapies: The Promise of Clinical Translation'. Over the past 60 years, a lot of trials have failed, probably in part because of disease heterogeneity. Implementing a precision medicine approach is vital. It is about making a hypothesis to be tested in different models involving biomarker-led clinical trials; an iterative process that requires access to blood & tissue from large patient cohorts.

Professor Benoit Van Den Eynde, director, Ludwig Institute for Cancer Research, added «Preclinical research in oncology has to change. One of the best ways to improve outcomes is to combine immunotherapies with something else, for example, radiotherapy. Only then will we start to see more improved outcomes for our patients.»

Read more of the news report

[Congress] World Molecular Imaging Conference – 4-7 September - Montreal

World Molecular Imaging Conference – 4-7 Septembre - Montreal

Explore our multi-modal pharmaco-imaging & targeted radiotherapy expertise for your preclinical projects:

  • Design & implementation of the radionuclide labeling of your chemical or biological molecules of interest
  • Biodistribution of therapeutic drugs using non-invasive techniques
  • Development of translational nuclear medicine biomarkers
  • Evaluation of targeted radiotherapy efficacy

Schedule a meeting to discuss your project and investigate how Oncodesign can support your pipeline!

This email address is being protected from spambots. You need JavaScript enabled to view it.


Venez discuter de notre large palette de services et solutions innovantes & les opportunités de licensing ou partenariat en oncologie, immuno-inflammation& maladie neurodégénératives.
%MCEPASTEBIN%

[Congress] Nordic Life Science Days - 10-12 September - Malmö, Copenhagen

[Congrès] Nordic Life Science Days - 10-12 Septembre - Malmö, Copenhague

 Looking for a partner that allows you to validate the efficacy of your molecule with proven proof of concept?

To find out more, meet Mike Brown, our sales manager, via the One-on-One partnership platform. He will present our expertise in vitro / vivo pharmacology, imaging & RTR, biomarkers as well as our offer in DMPK and bioanalysis performed in GLP environment.

All our offers are available for your therapeutic projects in inflammation, immunology, immuno-oncology, oncology and infectious diseases.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Access One-on-One Partnering platform

 

Nos expert seront présents:

Table ronde "Quoi de neuf autour de l’innovation en oncologie ? » Avec la participation de Mr. Sébastien Vachenc Responsable Data Sciences et Directeur de projet OncoSNIPE®

Session de Networking où nous dévoilerons nos compétences en oncologie/IO dans le cadre de notre consortium IMODI ainsi que notre large palette d’offres pour les maladies inflamatoires et maladies infectieuses ( depuis l’identification de cibles, la phase d’optimisation à la demande d’investigation du nouveau medicament (IND))

Oncodesign vous guide tout au long des processus de développement de votre candidat médicament.
A l'occasion du congrès annuel SNMMI, nous vous dévoilons notre expertise en pharmaco-imagerie et radiothérapie ciblée.